Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lamivudine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 3/20 | 0.91 |
| ▸ | LMNA | P02545 | 3/20 | 0.91 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.91 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.91 |
| ▸ | MAPT | P10636 | 2/20 | 0.91 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.91 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.91 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.91 |
| ▸ | POLG | P54098 | 3/20 | 0.67 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | MTOR | P42345 | 1/20 | 0.48 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.48 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.48 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.46 |
| ▸ | NT5E | P21589 | 1/20 | 0.41 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.39 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lamivudine SCHEMBL3472481 | 1.00 | ALB (0.91) | ALBLMNAPDE3ACACNA1FMAPT | |
| Lamivudine SCHEMBL3198505 | 1.00 | ALB (0.91) | ALBLMNAPDE3ACACNA1FMAPT | |
| Lamivudine SCHEMBL20266290 | 0.99 | ALB (0.89) | ALBLMNAPDE3ACACNA1FMAPT | |
| Lamivudine SCHEMBL2240686 | 0.95 | ALB (1.00) | ALBLMNAPDE3ACACNA1FMAPT | |
| Lamivudine SCHEMBL2806818 | 0.95 | ALB (1.00) | ALBLMNAPDE3ACACNA1FMAPT | |
| Lamivudine SCHEMBL12964486 | 0.95 | ALB (1.00) | ALBLMNAPDE3ACACNA1FMAPT | |
| Lamivudine SCHEMBL2422788 | 0.95 | ALB (1.00) | ALBLMNAPDE3ACACNA1FMAPT | |
| Lamivudine SCHEMBL465678 | 0.95 | ALB (1.00) | ALBLMNAPDE3ACACNA1FMAPT | |
| Lamivudine SCHEMBL12996723 | 0.95 | ALB (1.00) | ALBLMNAPDE3ACACNA1FMAPT | |
| Lamivudine SCHEMBL109675 | 0.95 | ALB (1.00) | ALBLMNAPDE3ACACNA1FMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 262 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119881137-A | Method and kit for detecting ultrahigh-polarity amphoteric compound on dry blood spot | 裕菁科技(上海)有限公司 | 2025-04-25 | — | — | CN | claimed |
| US-20220307066-A1 | AN ENZYMATIC ASSAY TO MEASURE LONG-TERM ADHERENCE TO PRE EXPOSURE PROPHYLAXIS AND ANTIRETROVIRAL THERAPY | UNIVERSITY OF WASHINGTON (US) | 2022-09-29 | — | — | US | claimed |
| WO-2020252399-A1 | AN ENZYMATIC ASSAY TO MEASURE LONG-TERM ADHERENCE TO PRE EXPOSURE PROPHYLAXIS AND ANTIRETROVIRAL THERAPY | UNIVERSITY OF WASHINGTON (US) | 2020-12-17 | — | — | WO | claimed |
| US-20100167268-A1 | SEROCONVERSION ASSAYS FOR DETECTING XENOTROPIC MURINE LEUKEMIA VIRUS-RELATED VIRUS | WHITTEMORE PETERSON INSTITUTE | 2010-07-01 | — | — | US | claimed |
| US-7611704-B2 | Compositions and methods for treating viral infections using antibodies and immunoconjugates to aminophospholipids | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2009-11-03 | — | — | US | claimed |
| US-7511124-B2 | Compositions comprising phosphatidylethanolamine-binding peptides linked to anti-viral agents | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2009-03-31 | — | — | US | claimed |
| US-7455833-B2 | Methods and compositions for treating viral infections using antibodies and immunoconjugates to aminophospholipids | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-11-25 | — | — | US | claimed |
| US-7384909-B2 | Anti-viral treatment methods using phosphatidylethanolamine-binding peptides linked to anti-viral agents | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-06-10 | — | — | US | claimed |
| CN-119881137-A | Method and kit for detecting ultrahigh-polarity amphoteric compound on dry blood spot | 裕菁科技(上海)有限公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-115181096-B | 3TC-PA compound bonded through ester bonds and application thereof | 湖北大学 | 2024-03-19 | — | — | CN | disclosed |
| CN-108727450-B | Liver delivery anti-hepatitis C prodrug nucleoside cyclic phosphate compound and application thereof | 浙江柏拉阿图医药科技有限公司 | 2024-02-20 | — | — | CN | disclosed |
| CN-117567448-A | Method for controlling lamivudine particle size distribution | 上海迪赛诺化学制药有限公司 | 2024-02-20 | — | — | CN | disclosed |
| CN-114099454-B | Lamivudine tablet and preparation method thereof | 长春海悦药业股份有限公司 | 2023-06-27 | — | — | CN | disclosed |
| US-20230172961-A1 | THERAPEUTICS FOR COVID-19 | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-06-08 | — | — | US | disclosed |
| WO-2003082848-A1 | PYRANON AND PYRANDION INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE | PFIZER INC. (US) | 2003-10-09 | — | — | WO | disclosed |
| WO-2003080078-A1 | TREATMENT OF PRE-CORE HEPATITIS B VIRUS MUTANT INFECTIONS | MITSUBISHI PHARMA CORPORATION (JP) | 2003-10-02 | — | — | WO | disclosed |
| WO-2003075009-A1 | USE OF NUCLOEOSIDE DERIVATIVES COMPRISING A CITRATE GROUP FOR PRODUCING ANTIBODIES HAVING AFFINITY FOR TRIPHOSPHORYLATED NUCLEOSIDES AND USES THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS (FR) | 2003-09-12 | — | — | WO | disclosed |
| US-20030109498-A1 | Antiviral agent for drug-resistant virus | MITSUBISHI PHARMA CORPORATION (JP) | 2003-06-12 | — | — | US | disclosed |
| EP-1225904-A2 | COMBINATIONS OF LAMIVUDINE AND ENTECAVIR FOR TREATMENT OF HEPATITIS B VIRUS INFECTION | GLAXO GROUP LIMITED (GB) | 2002-07-31 | — | — | EP | disclosed |
| WO-2001030329-A2 | COMBINATIONS OF LAMIVUDINE AND ENTECAVIR FOR TREATMENT OF HEPATITIS B VIRUS INFUCTION | GLAXO GROUP LIMITED (GB) | 2001-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230172961-A1 | THERAPEUTICS FOR COVID-19 | ACE, ACE2, PNP | ALB 3707/4885LMNA 3427/4885PDE3A 1722/4885 |
| US-20030109498-A1 | Antiviral agent for drug-resistant virus | TPMT, MTAP, TYMP | ALB 2161/4885LMNA 4643/4885PDE3A 3862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.